Full Press Release Details
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.
The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies (DEEs) including:
The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
The EMERALD study evaluating relutrigine for broader DEEs
The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE
To RSVP and attend the live event, you may click here. A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.
Contact Data
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.